New immune clues could unlock better b-cell cancer treatments
NCT ID NCT07499635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study will measure two immune system markers, CD305 and CD85d, on cancer cells from 180 people newly diagnosed with B-cell blood cancers. The goal is to see how these markers relate to different cancer types and patient outcomes. No treatment is given; the study only observes and analyzes cells to improve future diagnosis and therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Double-Targeted immune cells take aim at Hard-to-Treat blood cancers
- Double-Pronged immune cells take aim at blood cancers
- Double-Pronged CAR-T cells take aim at Hard-to-Treat blood cancers
- Off-the-Shelf CAR t cells take on tough blood cancers
- Hidden danger: why some patients can't shake COVID-19
- New drug HRS-1635 enters early human testing for hard-to-treat blood cancers